Kopran Limited (NSE: KOPRAN) has released its quarterly investor presentation for Q2 FY 2026-27, showcasing significant financial and operational highlights. The company, a global pharmaceutical powerhouse, reported robust revenue growth and operational performance across its API and Formulation segments.

Financial Highlights

The company’s revenue from operations for Q2 FY 2026-27 stood at Rs. 21,126 lakhs, marking a substantial increase from Rs. 15,399 lakhs in the same period last year. The EBITDA for the quarter was Rs. 1,822 lakhs, reflecting a healthy margin of 8.62%. Despite a forex loss of Rs. 219 lakhs, the net profit for the quarter was Rs. 439 lakhs, indicating a strong financial performance.

Operational Performance

Kopran Limited’s API segment continued to drive growth, with the company’s Atenolol and Carbapenem products leading the charge. The Formulations segment also performed well, with significant contributions from Anti-Diabetic and Anti-Hypertensive products. The company’s state-of-the-art manufacturing facilities in Maharashtra and Gujarat ensured high compliance with global regulatory standards.

Looking Ahead

Kopran Limited remains committed to driving sustainable growth through strategic imperatives such as capacity expansion, regulatory compliance, and cost optimization. The company’s focus on R&D and capacity enhancement positions it well for future growth and sustainability in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.

Emcure Pharmaceuticals Limited (NSE: EMCURE) showcased a robust performance in Q2FY27 with a 24.3% year-on-year operating revenue growth and a 29.3% PAT growth. The company’s disciplined execution and complex science have driven this compounding value. The operating revenue reached INR 28,205 Mn, while the PAT stood at INR 3,251 Mn. Notably, the EBITDA grew by 30.9% year-on-year, marking a 103 bps YoY improvement.

Domestic Business Performance

The domestic business continued its double-digit growth for the second consecutive quarter, improving from 10% in Q1FY27 to 12% in Q2FY27. Key brands such as Orofer XT, Orofer FCM, Rosuvas EZ, and Vylda showed significant growth, with Orofer XT and Orofer FCM growing by 39% each. Zuventus also demonstrated good traction with anchor brands like Zostum and Bevon growing by 34% and 17% respectively.

International Business Performance

Internationally, the company delivered strong performance across the UK, EU, and Canada. The RoW segment saw a growth acceleration supported by new launches in LATAM, CIS, Asia, and Africa. The company’s product pipeline provides visibility for sustained medium-term growth. The company expects continued growth over the full year as its strengthened team and portfolio gain traction.

Emcure Pharmaceuticals Limited remains committed to its strategic vision and continues to simplify its group holding structure to achieve synergies in backend operations and corporate functions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure posts a 2.1% three-month gain, but softens in the last few weeks. The business compounds revenue at 15.4% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 5.8% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 15.4% and profits at 20.2%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.69 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.

Gland Pharma Limited (GLAND) has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Methylprednisolone Acetate Injectable Suspension USP. This approval covers Single-Dose and Multiple-Dose Vials, including 40 mg/mL and 80 mg/mL Single-Dose Vials and 200 mg/5 mL, 400 mg/10 mL, and 400 mg/5 mL Multiple-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Depo-Medrol Injectable Suspension, of Pfizer Inc. Notably, the Methylprednisolone injection had US sales of approximately USD 214 million for the twelve months ending August 2026, according to IQVIA.

Significance of the Approval

This approval marks a significant milestone for Gland Pharma Limited, reinforcing its position as a leading injectable-focused pharmaceutical company. The product is indicated for the treatment of various conditions including Allergic States, Dermatologic Diseases, Endocrine Disorders, and more. The approval will enable Gland Pharma to expand its product portfolio and cater to a broader range of therapeutic needs.

Company’s Growth and Market Presence

Established in 1978, Gland Pharma has grown from a contract manufacturer to one of the largest injectable-focused companies globally. With a presence in over 60 countries, the company operates primarily under a business-to-business (B2B) model. It has a wide range of injectables including vials, ampoules, pre-filled syringes, and more. This approval further strengthens Gland Pharma’s reputation in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 24.3% over three months and trades near its 52-week highs. The PEG stands at 4.62 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.3% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. The stock trades at 92% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 21.3% and profits at 9.6%, with D/E of 0.03. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.62 premium is usually justified. Check Fundamentals of Gland Pharma Limited.